We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





ECCMID 2022 Takes Place for the First Time as Hybrid Event Both Onsite and Online

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: ECCMID 2022 took place in Lisbon, Portugal from April 23-26 (Photo courtesy of ESCMID)
Image: ECCMID 2022 took place in Lisbon, Portugal from April 23-26 (Photo courtesy of ESCMID)

The 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) took place in Lisbon, Portugal from April 23-26 – for the first time as a hybrid event both onsite and online.

ECCMID is the world’s premier clinical microbiology & infectious diseases event organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program.

ECCMID 2022 offered excellent opportunities to corporate partners to showcase their latest findings, share their experiences and knowledge and demonstrate practical techniques and guidance. A comprehensive program covered the entire range of ECCMID topics with high-level speakers. Participants had the opportunity to meet researchers from many parts of the world to discuss methods, results and the impact on clinical and laboratory practice. Additionally, young professionals had the opportunity to discuss their ideas and projects with renowned experts in a variety of interactive sessions that also provided networking opportunities.

This year’s ECCMID once again featured pipeline corners where innovative companies and research groups were offered a platform to present their early-stage antimicrobial therapies, diagnostic products in development, and research funding opportunities to a wider audience. This was complemented by scientific content co-developed with the industry such as the integrated symposia.

Other new features from ECCMID 2021 that returned this year were the Keynote Fireplace sessions where ECCMID keynote speakers met with a small group of participants to enter a more in-depth discussion on their keynote lecture. Additionally, the infectious disease-themed Escape Room was reprised and updated as an immersive interactive addition.

Related Links:
ESCMID 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test can find tRNA fragments unique to Parkinson’s disease before patients even have symptoms (Photo courtesy of Shutterstock)

Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease

Currently, no reliable blood test exists for diagnosing Parkinson’s disease. Instead, physicians rely on observing a patient's movements, but this qualitative method has an error rate of 20%-25% and can... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.